Perfluorooctane sulfonate (PFOS) and perfluorooctane acid (PFOA) are widely distributed environmentally persistent organic pollutants found at low levels in human and wildlife ecosystem. The objectives of the current study were to investigate toxicokinetic behaviors and modes of PFOS and PFOA on tilapia (Oreochromis niloticus). The toxicokinetic behaviors and modes of PFOS and PFOA are different in tilapia during experimental periods. Exposure to both PFOS and PFOA was approximately 5 to 6 times higher for male tilapia than for female tilapia. The terminal half-life of PFOA in serum was about 4 times longer for male tilapia than for female tilapia. The apparent volume of distribution for PFOS and PFOA in the serum was about 3 to 4 times higher for female tilapia than for male tilapia. The lymphocytes level decreased rapidly with the increased PFOA concentration. A similar pattern was observed with the PFOS exposure, and it is remarkable that PFOS and PFOA were significantly accumulated in both PFOS and PFOA exposure but PFOA showed a greater effect than PFOS. PFOA blood concentrations were lesser than the limit of quantification in non-exposure tilapia during an uptake period, while measured PFOS concentrations were at least six times lesser than those in PFOS exposure. Tilapia weight gain was also decreased with statistical significance in all PFOA-treated groups, and the effect of PFOA was higher than that of PFOS. The effects of PFOA in survival percent were more pronounced in this case than that of PFOS. Moreover, PFOA had similar mode, and PFOS and PFOA can inhibit the 17β-HSD3 enzyme activity of tilapia.
INTRODUCTION
Many products of perfluorinated compounds (PFCs) are becoming ubiquitous in human and wildlife environment because of the continuous use of such products (Giesy and Kannan, 2002; Olsen et al., 2005) and the two PFCs that have received the greatest attention are perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA). In a monitoring study of human serum PFOS was determined collected from the general public, to be the most abundant PFC followed by PFOA (Kannan et al., 2004) . While exposure pathways of PFOA and PFOS to humans and aquaculture have not yet been fully elucidated, the consumption of fish (Falandysz et al., 2006) and farm animals (Guruge et al., 2005 ) have been suggested as major contributors of PFOS and PFOA to exposed human populations.
A few pharmacokinetic studies with PFOA or PFOS have been conducted with mammals such as rats, dogs and monkeys (Seacat et al., 2002; Kudo et al., 2002; Lau et al., 2004) , but, the details of the toxicokinetic profile and modes of PFOS and PFOA have not been published Afr. J. Biotechnol. with aquatic animals. PFOS and PFOA are readily absorbed and are poorly eliminated from blood and other tissues with biological half-time for depuration that can range from several weeks to months, depending on the species and sex. Previously, it has been reported that repeated dose toxicity with PFOS and PFOA in mice, rats and monkeys (Seacat et al., 2002 (Seacat et al., , 2003 Luebker et al., 2005; Thibodeaux et al., 2003; Lau et al., 2003) have shown that body burden is proportional to cumulative dose at lower and moderate experimental doses.
To control effectively the exposures to PFOS and PFOA, it is necessary to understand the kinetic mechanism and metabolism of PFOS and PFOA in the environment. Therefore, the objective of our study was to explore the toxicokinetic behaviors and modes of PFOS and PFOA in tilapia and evaluate if the pharmacokinetic profile and modes of PFOS and PFOA are similar to tilapia after oral administration.
MATERIALS AND METHODS

Experimental design
A total of 60 freshwater tilapia (Oreochromis niloticus) 20 to 30 g each (30 females and 30 males) were collected from a local fish farm at the industrial and agricultural areas. They were kept in a 300 L fiber-glass tank with recirculating water for 3 weeks (22 ± 0.5°C, 12 h light / 12 h dark cycles). Tilapia were randomly divided into three groups (sex for each group) in which they were treated with PFOS and PFOA in the form of pelleted dry feed at a dose of 0, 1.0, 5.0 and 10.0 mg/L, respectively for 24, 48, 72, 96, 120 , and 144 h.
The fish were fed once every other day with commercial fish food. Doses applied in this study were designed based on the pharmacological and toxicological studies, and PFOS and PFOA were found to be effective at range of 1 to 20 mg/g. The fish were then killed immediately by a blow on the head and samples of the muscle, liver were taken, the samples were stored at −40°C until used.
Sample preparation and analysis
Blood samples were collected with an ion-pairing method with some modifications (Kannan et al., 2004) . Measurement of PFOS and PFOA in blood or tissues was conducted using HPLC with high resolution and electro-spray tandem mass spectrometry (HPLC-MS/MS). Serum was prepared by standard methods. Serum samples were stored frozen (−20°C) until analysis using a validated HPLC-MS/MS method. Hemolymphs were instantly mixed with the same volume of ACD (1.5% citric acid, 2.5% trisodium citrate, 2% D-glucose) solution, and were kept frozen at −70°C. Hemolymph were thawed and vortexed to assure homogeneity before extraction.
0.5 ml of hemolymph were placed into 10 ml polypropylene centrifuge, then 7.0 ml of the extraction solution (1 M HCl acetonitrile (4/500, v/v) was add. The tubes were vortexed for 2 min and centrifuged at 8000 rpm for 10 min and 4°C. The resulting clear supernatant was dried using a vortex evaporator and reconstituted in 1.0 ml of mobile phase. After filtration with 0.45 µm disposable syringe (filter units equipped with cellulose acetate membranes), the filtrate was injected into the HPLC system (Tang and Yang, 2006) .
Preparation of microsomal protein and 17β-HSD3 activity assay
Microsomal preparations of human and rat testes were done as described previously (Hu et al., 2009) . Microsomal protein concentrations were adjusted to 4 mg/ml and used for measurement of 17β-HSD3 activities. 17β-HSD3 activity in spermary microsomes was recorded using the normal procedures (Hu et al., 2009 ).
Toxicokinetic analysis
All pharmacokinetic parameters were calculated using noncompartmental analysis from the individual concentrations of PFOS and PFOA in serum for tilapia and from the mean concentrations in serum, lymphocytes and blood. The data could not be consistently fit to a one-compartment model using WinNonlin version 5. 
Statistical analysis
Assays were repeated three times. The IC50 was calculated using GraphPad version 4.0 using nonlinear regression of curve fit with one-site competition. Data were subjected to analysis by one-way ANOVA followed by Duncan multiple comparison test to identify significant differences between groups when three groups were calculated. All data were expressed as means ± SEM. Differences were regarded as significant at P<0.05.
RESULTS AND DISCUSSION
Toxicokinetic behaviors of PFOS and PFOA in serum
The serum concentrations of PFOS and PFOA following oral administration dose of 5 mg/g are illustrated in Figure  1 . Systemic exposures to PFOA were approximately 2 to 3 times higher than exposures to PFOS at equivalent dosages. This is partially due to a terminal half-life for PFOS that is shorter than that for PFOA. Exposure to both PFOS and PFOA was approximately 5 to 6 times higher for male tilapia than for female tilapia, this may be attributable to several related factors such as the shorter half-life, higher apparent clearance and higher distribution numbers of females than for males.
The terminal half-life of PFOS in serum was approximately 2-fold shorter for female tilapia (1.0 h) than for male tilapia (2.0 h). The terminal half-life of PFOA in serum was about 4-fold longer for male tilapia (1.4 h) than female tilapia (0.35 h). Apparent clearance of PFOS and PFOA from the serum was roughly 5 to 6 times higher for female tilapia than for male tilapia. The apparent volume of distribution for PFOS and PFOA in the serum was about 3 to 4 times higher for female tilapia than for male tilapia. Lower apparent volumes of distribution for both female and male may reflect rapid clearance, including protein binding, and elimination. The serum concentrations of PFOS and PFOA followed repeated oral doses of 10 mg/g, respectively for male and female tilapia. Oral administration of PFOS and PFOA resulted in systemic exposure, which was proportional to the dosage level. Exposure tended to decrease upon repeated dosing. The terminal half-life of PFOS and PFOA in serum, however, was about 1 to 2 h regardless of dosage level, gender or number of doses. Studies with PFOS and PFOA in rats have demonstrated a sexspecific difference in elimination, with females more actively excreting these materials via the kidney than males (USEPA OPPTS, 2002; Vanden Heuval et al., 1991) . This difference contributes to large differences in toxicokinetic behavior. For example, Vanden Heuval et al. (1991) reported that the half-life for 14 C-PFOA was 9 days for male rats and 4 h for female rats. Ylinen at al. (1990) reported a half-life of 24 h in female and 105 h in males Wistar rats. In the study, there was also appreciable gender difference in the half-life of PFOS and PFOA in serum of tilapia following oral doses.
Toxicokinetic behaviors of PFOS and PFOA in peripheral lymphocytes
The PFOS and PFOA concentration-time curves for the tests showed instant absorption followed by distribution phase as shown in Figure 2 . After an oral administration of 5.0 mg/g body weight of tilapia, the peripheral lymphocytes PFOA concentration peaked at 600.09 ± 15.8 ng/ml at the first sampling time of 24 h and then the lymphocytes PFOA concentration decreased rapidly from 600.09 ± 15.8 to 468.32 ± 12.6 ng/ml post-treatment. A second absorption peak (480.65 ± 9.5 ng/ml) was observed at 96 h post administration, after which the PFOA concentration declined slowly and continuously until the end of the experiment. A similar pattern and dosage was observed with the PFOS exposure, including a peak lymphocytes PFOS concentration of 453.0 ± 8.6 ng/ml at the first sampling time of 24 h and a second absorption peak (385.78 ± 11.4 ng/ml) at 72 h posttreatment.
It is possible that there is recirculation of PFOS and PFOA, resulting in second absorption peaks. The lymphocytes PFOS and PFOA concentration at 5.0 mg/g dosage body weight were analyzed with pharmacokinetics software (DAS ver 1.0), and both could be described by a two compartment open model with firstorder absorption. Both the absorption half-time (T 1/2Ka ) and the lag time before initiation of absorption (T lag ) were approximately zero. With respect to apparent volume of distribution and total body clearance, no significant differences were observed between PFOS and PFOA. The distribution rate constant (α) of PFOS in lymphocytes was approximately 1.5-fold lesser than for PFOA, and the elimination rate constant (β) of PFOS in lymphocytes was about 2-fold higher than for PFOA. the peripheral lymphocytes concentration-time curve (AUC 0-∞ ) for PFOA was 2-fold that of the lymphocytes PFOS concentration. It is remarkable that PFOS and PFOA were significantly accumulated in our study in both PFOS and PFOA exposure, with PFOA showing a greater effect than PFOS. Similar results have been observed in few fishes, such as the zebrafish (Huang et al., 2010) and common carp (Cyprinus carpio) (Hoff et al., 2003a) .
Uptake and elimination behaviors of PFOS and PFOA in blood
A one-compartment model was used to describe the elimination behavior of PFOS or PFOA from blood in tilapia according to the equation: in (C t /C 0 )=-kt, where C t is the concentration of PFOS or PFOA at the time (t) in an elimination phase, C 0 is the concentration at the onset of depuration (ng/mL) and k is the elimination rate constant.
The time-course concentrations of PFOS and PFOA released from oral administration of different uptake profiles in tilapia blood over an exposure period was recorded. The maximum PFOS and PFOA concentrations in blood taken from same dosage treatment were 7.3 × 103 and 9.6 × 103 ng/ml at primary exposure time (24 h), respectively ( Figure 3 ). Subsequently, introduced PFOS fluctuated over 72 h uptake period, while PFOA in 5.0 mg/ml treatment had an increase at 24 h followed by decreased blood levels in later exposure periods. PFOA blood concentrations were lesser than the limit of quantification in non-exposure tilapia during an uptake period, while measured PFOS concentrations were at least six times lesser than those in PFOS exposure. Concentrations of PFOS and PFOA in blood reflected the dose from oral administration target PFCs. Nevertheless, elimination rates of PFOS and PFOA from blood of tilapia were significantly different (Figure 3) . Concentrations of PFOS in blood decreased rapidly during the depuration phase, with PFOS concentrations at the termination of depuration being 56 to 59% as compared to those at the beginning of depuration. However, only 18 to 23% reduction of PFOA was eliminated from the blood during the same exposure period. The elimination half-time (t 1/2 ) of treatmentaveraged PFOS (10.6 h) was almost four-fold more than that of treatment-averaged PFOA (42.5 h). The elimination rate constant of PFOS and PFOA was 0.12 ± 0.01 and 0.03 ± 0.002 h -1 with the same dosage, respectively. Concentrations of PFOS and PFOA were similar during the depuration period to those measured during the exposure period in control group. Different elimination kinetics were observed even though PFOS and PFOA are structurally similar anionic surfactants that possess some similar physico-chemical properties such as pKa, Henry's Law constant, and similar hydrophobicity based on critical micelle concentration (Giesy and Kannan, 2002; Kissa, 2001 ).
Dose-response modes of PFOS and PFOA on weight and percent survival
We chose 144 h as the standard incubation time for the experiments according to the primary experiment. Tilapia weights, as an average of each experiment group, are presented in Figure 4A and were decreased with statistical significance in all PFOS-treated groups. Tilapia weight gains were also decreased with statistical significance in all PFOA-treated groups, and the effect of PFOA was higher than that of PFOS. It appears that there is positive dependence between PFOS and PFOA concentration and tilapia weight to PFOS and PFOA exposure environment, represented with a high coefficient of correlation (p = 0.021, R = 0.9316 for PFOS and R = 0.9258 for PFOA). Figure 4B presents data for the mean percent of tilapia that survived in each experiment group. The mean percent survival of live born tilapia was decreased in a dose-dependent manner and became statistically significant in the 5.0 and 10.0 mg/l oral administration dose groups for PFOS-treated groups. The mean percent survival of live tilapia decreased from 88 to 26% with 0 and 10.0 mg/L PFOA exposure, respectively. Furthermore, the effects of PFOA in percent survival were more pronounced in this case than that of PFOS. Multiple linear regression analysis revealed a significant correlation between PFOS and PFOA concentration and survival (p = 0.011, R = 0.9056 for PFOS and R = 0.9403 for PFOA).
Inhibition modes of PFOS and PFOA on 17β-HSD3 activity
17β-HSD3 levels were determined only in male tilapia. Activity of the 17β-HSD3 enzyme, which catalyzes the conversion of androstenedione to testosterone, was measured in male tilapia spermary microsomes in the presence of PFOS and PFOA exposure. Figure 5 shows the effect of PFOS and PFOA on 17β-HSD3 activities when tested at different concentrations, respectively. 17β-HSD3 activity was strongly reduced by PFOS, which is also in a dose-dependent manner. The activities of the tilapia 17β-HSD3 enzymes in the absence of PFOS were determined to be 5.36 ± 0.06 nmol/mg protein/min. PFOS inhibited the tilapia 17β-HSD3 enzyme by 15, 60 and 88% as compared to control at the oral dose of 1.0, 5.0, and 10.0 mg/L, respectively. Moreover, PFOA had similar mode, PFOA inhibited the tilapia 17β-HSD3 enzyme by 23, 75 and 93% as compared to control at the oral dose of 1.0, 5.0, and 10.0 mg/L, respectively. The IC 50 for PFOS and PFOA in the inhibition of tilapia 17β-HSD3 activity were determined to be 4.18 ± 0.05 and 5.33 ± 0.02, whereas the IC 50 of PFOS and PFOA in the inhibition of tilapia 17β-HSD3 activity were 102 and 106 nmol/mg protein min, respectively as previously reported (Chu et al., 2009 ). The mode of PFOS and PFOA inhibition of tilapia 17β-HSD3 activity differs from that previously reported for the rat enzyme in and PFOS and PFOA inhibited rat 17β-HSD3 activity with competitive inhibition on substrate DIONE binding site and noncompetitive inhibition on cofactor NADPH binding site of the enzyme (Zhao et al., 2010; Chu et al., 2009 ). The biological roles of 11β-HSD2 in fish are complex. 11β-HSD2 is expressed in fish liver, kidney, brain and reproductive organs (Michael and Baker, 2004; Zhao et al., 2010) . 11β-HSD2 and 17β-HSD3 catalyzes the conversion of 11β-hydroxytestosterone and androstenedione to 11-keto-testosterone, a fish androgen, consistent with the presence of 11β-HSD2 and 17β-HSD3 in gonads. Fish 11β-HSD2 and 17β-HSD3 are expressed in testis (Michael and Baker, 2004; Zhao et al., 2010) , where they can both inactivate cortisol and synthesize 11-keto-testosterone.
Conclusion
The results present in this study showed that though they are structurally similar, the toxicokinetic behaviors and modes of PFOS and PFOA are different in tilapia during experimental periods. The toxicokinetics behaviors and modes of PFOS and PFOA were estimated after oral administration to the tilapia. Systemic exposures to PFOA were approximately 2 to 3 times higher than exposures to PFOS at equivalent dosages; this is partially due to a terminal half-life for PFOS that is shorter than that for PFOA. Exposure to both PFOS and PFOA was approximately 5 to 6 times higher for male tilapia than for female tilapia. The terminal half-life of PFOA in serum was about 4 times longer for male tilapia than female tilapia. The apparent volume of distribution for PFOS and PFOA in the serum was about 3 to 4 times higher for female tilapia than for male tilapia. Lower apparent volumes of distribution for both female and male may reflect rapid clearance, including protein binding and elimination. After an oral administration of 5.0 mg/g body weight of tilapia, the peripheral lymphocytes PFOA concentration peaked at 600.09 ± 15.8 ng/ml at the first sampling time of 24 h and then the lymphocytes PFOA concentration decreased rapidly from 600.09 ± 15.8 to 468.32 ± 12.6 ng/ml post-treatment. A similar pattern was observed with the PFOS exposure. With respect to apparent volume of distribution and total body clearance, no significant differences were observed between PFOS and PFOA. The distribution rate constant (α) of PFOS in lymphocytes was approximately 1.5 times lesser than for PFOA, and the elimination rate constant (β) of PFOS in lymphocytes was about 2 times higher than for PFOA. It is remarkable that PFOS and PFOA were significantly accumulated in both PFOS and PFOA exposure, with PFOA showing a greater effect than PFOS. PFOA blood concentrations were lesser than the limit of quantification in non-exposure tilapia during an uptake period, while measured PFOS concentrations were at least six times lesser than those in PFOS exposure. Tilapia weight gains were also decreased with statistical significance in all PFOA-treated groups, and the effect of PFOA was higher than that of PFOS. The effects of PFOA on percent survival were more pronounced than that of PFOS. Moreover, PFOS and PFOA can inhibit the 17β-HSD3 enzyme activity of tilapia.
